NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

As previously disclosed, in February, March and April of 2018, the Company and its Chief Executive Officer, Linda F. Powers, entered into demand notes for short-term bridge loans of $5.4 million from Ms. Powers to the Company. The notes have remained outstanding to date. On November 11, 2018, the Company and Ms. Powers agreed to extend the notes to a maturity of one year following the respective funding dates. In consideration of the continuing forbearance, the Company will issue warrants representing 50% of the amounts due under the loans from Ms. Powers. The warrants will have the same exercise price and exercise period as the warrants issued to the investors who loaned the Company $5 million.

Between October 2, 2018 and November 1, 2018, approximately $439,000 principal and $17,000 of accrued interest on certain notes were converted into approximately 3.1 million shares of common stock.